JAZZ Hits 52-Week High on Encouraging Gastric Cancer Study Data

Key Takeaways JAZZ shares surged after positive late-stage HERIZON-GEA-01 results in first-line HER2 GEA.The study showed significant PFS gains and strong OS outcomes for Ziihera-based regimens.JAZZ plans to seek Ziihera label expansion in 2026 following these first late-stage results.Shares of Jazz Pharmaceuticals (JAZZ) rose nearly 21% on Monday after it announced positive top-line results from the late-stage HERIZON-GEA-01 study. This study evaluated different combination regimens involving Ziihera (zani ...